Earnings History Data for Akebia Therapeutics, Inc. (AKBA) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Akebia Therapeutics, Inc.

Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
08-11-2023	PM		AKBA	Akebia Therapeutics, Inc.	188.31	-0.08	-0.09	-0.28	Akebia GAAP EPS of -$0.08 beats by $0.01, revenue of $42.05M misses by $6.13M [11/8/2023 7:33 AM]	0.9601	-0.13 (-11.92%)	1.06	-0.03 (-2.76%)	0.24 - 1.84	2,613,648	1,770,000	86,029
Akebia Q3 2023 Earnings Preview [11/7/2023 12:05 PM] Akebia GAAP EPS of -$0.08 beats by $0.01, revenue of $42.05M misses by $6.13M [11/8/2023 7:33 AM]
25-08-2023	PM		AKBA	Akebia Therapeutics, Inc.	234.27	-0.06	-0.03	0.23	Akebia GAAP EPS of -$0.06 misses by $0.03, revenue of $56.38M misses by $2.72M [8/25/2023 12:11 PM]	1.15	-0.10 (-8.40%)	1.27	0.02 (1.60%)	0.24 - 1.84	2,464,815	1,220,000	83,471
Akebia Q2 2023 Earnings Preview [8/24/2023 11:21 AM] Akebia plans to resubmit vadadustat NDA by end of Q3 [8/24/2023 10:15 AM] Akebia GAAP EPS of -$0.06 misses by $0.03, revenue of $56.38M misses by $2.72M [8/25/2023 12:11 PM]
08-05-2023	PM	Before the open (May 8)	AKBA	Akebia Therapeutics, Inc.	171.31	-0.14	-0.15	-0.35	Akebia GAAP EPS of -$0.14 beats by $0.01, revenue of $40.13M misses by $6.55M [5/8/2023 7:32 AM]	1.05	-0.04 (-3.33%)	1.06	-0.03 (-2.75%)	0.24 - 1.20	2,319,009	1,560,000	302,951
Akebia GAAP EPS of -$0.14 beats by $0.01, revenue of $40.13M misses by $6.55M [5/8/2023 7:32 AM]
09-03-2023	PM	Before the open (Mar 9)	AKBA	Akebia Therapeutics, Inc.	127.28	-0.04	0.00	-0.40	Akebia GAAP EPS of -$0.04 beats by $0.15, revenue of $55.18M beats by $7.78M [3/9/2023 7:42 AM]	0.8013	-0.23 (-22.20%)	0.84	-0.19 (-18.45%)	0.24 - 2.93	5,701,206	2,690,000	1,133,224
Akebia GAAP EPS of -$0.04 beats by $0.15, revenue of $55.18M beats by $7.78M [3/9/2023 7:42 AM] Akebia off 24% after 2023 revenue range comes in below consensus [3/9/2023 10:57 AM] Akebia stock slumps ~20% amid 'cautious' outlook for Auryxia FY23 sales [3/9/2023 11:33 AM]
03-11-2022	AH	4:05 PM ET (Nov 3)	AKBA	Akebia Therapeutics, Inc.	49.82	-0.28	-0.14	-0.34	Akebia reports mixed Q3 earnings; reaffirms FY22 Auryxia net product revenue guidance [11/3/2022 4:35 PM]	0.2760	-0.01 (-3.19%)	0.27	-0.02 (-5.30%)	0.24 - 3.30	1,423,893	1,250,000	196,709
Akebia reports mixed Q3 earnings; reaffirms FY22 Auryxia net product revenue guidance [11/3/2022 4:35 PM] Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Nov-02-22 04:05PM] Akebia Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights [Nov-03-22 04:05PM] Akebia Therapeutics (AKBA) Reports Q3 Loss, Tops Revenue Estimates [Nov-03-22 06:45PM]
04-08-2022	AH	4:05 PM ET (Aug 4)	AKBA	Akebia Therapeutics, Inc.	78.00	0.23	-0.29	-0.51	Akebia GAAP EPS of $0.15 beats by $0.48, revenue of $126.76M beats by $77.06M [8/4/2022 4:19 PM]	0.3950	-0.02 (-3.66%)	0.39	-0.02 (-4.51%)	0.30 - 3.35	6,038,127	4,470,000	670,291
Akebia GAAP EPS of $0.15 beats by $0.48, revenue of $126.76M beats by $77.06M [8/4/2022 4:19 PM] Akebia Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights [Aug-04-22 04:05PM] Akebia Therapeutics Announces Initial Findings from Investigator-Sponsored Clinical Study Evaluating Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Subjects with COVID-19 and Hypoxemia (VSTAT) [Aug-04-22 04:02PM] Akebia Therapeutics (AKBA) Surpasses Q2 Earnings and Revenue Estimates [Aug-04-22 07:25PM] Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study [Aug-05-22 11:12AM]
09-05-2022	AH	4:00 PM ET (May 9)	AKBA	Akebia Therapeutics, Inc.	75.96	-0.35	-0.27	-0.45	Akebia GAAP EPS of -$0.35 misses by $0.06, revenue of $61.7M beats by $17.48M [5/9/2022 4:20 PM]	0.4151	0.07 (20.18%)	0.38	0.03 (10.05%)	0.34 - 4.33	13,817,855	10,395,840	228,249
Akebia GAAP EPS of -$0.35 misses by $0.06, revenue of $61.7M beats by $17.48M [5/9/2022 4:20 PM] Akebia Therapeutics Reports First Quarter 2022 Financial Results and Business Update [May-09-22 04:05PM] Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates [May-09-22 06:25PM]
04-11-2021	PM	8:00 AM ET (Nov 4)	AKBA	Akebia Therapeutics, Inc.	546.30	-0.34	-0.32	-0.42	Akebia EPS misses by $0.03, misses on revenue [11/4/2021 8:08 AM]	3.04	-0.30 (-8.98%)	3.04	0.0 (0.00%)	2.30 - 5.14	2,697,636	2,030,000	2,014
Akebia EPS misses by $0.03, misses on revenue [11/4/2021 8:08 AM] Q3 2021 misses for Akebia Therapeutics leads to share decline [11/4/2021 12:10 PM] Akebia Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones [Nov-04-21 08:05AM] Akebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates [Nov-04-21 09:25AM]
05-08-2021	PM	8:00 AM ET (Aug 5)	AKBA	Akebia Therapeutics, Inc.	395.48	-0.51	-0.30	-0.44	Akebia EPS misses by $0.20, revenue in-line [8/5/2021 8:03 AM]	2.86	0.38 (15.12%)	2.44	-0.04 (-1.61%)	2.09 - 11.57	5,235,651	3,740,000	47,857
Akebia EPS misses by $0.20, revenue in-line [8/5/2021 8:03 AM] Akebia Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones [Aug-05-21 07:58AM] Akebia Therapeutics (AKBA) Reports Q2 Loss, Misses Revenue Estimates [Aug-05-21 09:15AM] Akebia Therapeutics, inc (AKBA) Q2 2021 Earnings Call Transcript [Aug-05-21 04:31PM] Why Akebia Therapeutics Stock Is Soaring Today [Aug-05-21 04:00PM]
10-05-2021	PM	8:00 AM ET (May 10)	AKBA	Akebia Therapeutics, Inc.	508.51	-0.45	-0.33	-0.47	Akebia EPS misses by $0.08, beats on revenue [5/10/2021 8:06 AM]	2.90	-0.21 (-6.89%)	3.08	-0.04 (-1.28%)	2.09 - 13.71	3,553,865	3,050,000	29,807
Akebia EPS misses by $0.08, beats on revenue [5/10/2021 8:06 AM] Akebia Therapeutics, Inc. to Host Earnings Call [May-10-21 07:15AM] Akebia Reports First Quarter 2021 Financial Results and Highlights Recent Company Milestones [May-10-21 08:00AM] Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates [May-10-21 09:20AM]
25-02-2021	PM	8:00 AM ET (Feb 25)	AKBA	Akebia Therapeutics, Inc.	641.75	-0.60	-0.43	-0.61	Akebia EPS misses by $0.22, beats on revenue [2/25/2021 8:02 AM]	3.46	-0.82 (-19.16%)	3.86	-0.42 (-9.81%)	2.09 - 13.71	13,605,442	6,865,401	710,398
Akebia EPS misses by $0.22, beats on revenue [2/25/2021 8:02 AM] Akebia shares slide following disappointing Q4 results [2/25/2021 9:16 AM]
05-11-2020	PM	7:00 AM ET (Nov 5)	AKBA	Akebia Therapeutics, Inc.	346.83	-0.42	-0.23	-0.28	Akebia EPS misses by $0.19, misses on revenue [11/5/2020 8:06 AM]	2.49	-0.08 (-3.11%)	2.49	0.0 (0.00%)	2.09 - 13.71	8,357,554	10,997,197	4,740

10-08-2020	PM	7:00 AM ET (Aug 10)	AKBA	Akebia Therapeutics, Inc.	1,580	-0.44	-0.46	-0.30		10.70	-0.28 (-2.55%)	10.98	0.0 (0.00%)	2.99 - 13.71	400,360	924,009	32,444

05-05-2020	PM	7:50 AM ET (May 5)	AKBA	Akebia Therapeutics, Inc.	1,040	-0.47	-0.63	-0.44	Akebia EPS beats by $0.16, beats on revenue [5/5/2020 7:41 AM]	11.85	3.19 (36.84%)	10.29	1.63 (18.82%)	2.99 - 12.02	6,325,513	870,332	454,965